<?xml version='1.0' encoding='utf-8'?>
<document id="31172535"><sentence text="Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects."><entity charOffset="149-158" id="DDI-PubMed.31172535.s1.e0" text="Avadomide" /><entity charOffset="160-166" id="DDI-PubMed.31172535.s1.e1" text="CC-122" /><pair ddi="false" e1="DDI-PubMed.31172535.s1.e0" e2="DDI-PubMed.31172535.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s1.e0" e2="DDI-PubMed.31172535.s1.e1" /></sentence><sentence text="Avadomide (CC-122) is a novel immunomodulatory drug that binds to cereblon, a member of the Cullin 4-RING E3 ubiquitin ligase complex"><entity charOffset="0-9" id="DDI-PubMed.31172535.s2.e0" text="Avadomide" /><entity charOffset="11-17" id="DDI-PubMed.31172535.s2.e1" text="CC-122" /><pair ddi="false" e1="DDI-PubMed.31172535.s2.e0" e2="DDI-PubMed.31172535.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s2.e0" e2="DDI-PubMed.31172535.s2.e1" /></sentence><sentence text=" Avadomide has multiple pharmacologic activities including potent immune modulation, antiangiogenic, antitumor, and antiproliferative activity and is being evaluated as an oncology treatment for hematologic malignancies and advanced solid tumors"><entity charOffset="1-10" id="DDI-PubMed.31172535.s3.e0" text="Avadomide" /></sentence><sentence text=" In vitro study has indicated that cytochrome P450 (CYP) 3A and CYP1A2 appear to be the major enzymes involved in the oxidative metabolism of avadomide"><entity charOffset="142-151" id="DDI-PubMed.31172535.s4.e0" text="avadomide" /></sentence><sentence text=" The effects of CYP3A inhibition/induction and CYP1A2 inhibition on the pharmacokinetics of avadomide in healthy adult subjects were assessed in 3 parts of an open-label, nonrandomized, 2-period, single-sequence crossover study"><entity charOffset="92-101" id="DDI-PubMed.31172535.s5.e0" text="avadomide" /></sentence><sentence text=" Following a single oral dose of 3 mg, avadomide exposure when coadministered with the CYP1A2 inhibitor fluvoxamine was 154"><entity charOffset="39-48" id="DDI-PubMed.31172535.s6.e0" text="avadomide" /><entity charOffset="104-115" id="DDI-PubMed.31172535.s6.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.31172535.s6.e0" e2="DDI-PubMed.31172535.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s6.e0" e2="DDI-PubMed.31172535.s6.e1" /></sentence><sentence text="81% and 107" /><sentence text="59% of that when administered alone, for area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf ) and maximum observed plasma concentration (Cmax ), respectively" /><sentence text=" Avadomide exposures, when coadministered with the CYP3A inhibitor itraconazole, were 100"><entity charOffset="1-10" id="DDI-PubMed.31172535.s9.e0" text="Avadomide" /><entity charOffset="67-79" id="DDI-PubMed.31172535.s9.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.31172535.s9.e0" e2="DDI-PubMed.31172535.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s9.e0" e2="DDI-PubMed.31172535.s9.e1" /></sentence><sentence text="0% and 93" /><sentence text="64% of that when administered alone, for AUC0-inf and Cmax , respectively" /><sentence text=" Avadomide exposures when coadministered with the CYP3A inducer rifampin were 62"><entity charOffset="1-10" id="DDI-PubMed.31172535.s12.e0" text="Avadomide" /><entity charOffset="64-72" id="DDI-PubMed.31172535.s12.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31172535.s12.e0" e2="DDI-PubMed.31172535.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s12.e0" e2="DDI-PubMed.31172535.s12.e1" /></sentence><sentence text="83% and 88" /><sentence text="17% of that when administered alone, for AUC0-inf and Cmax , respectively" /><sentence text=" Avadomide was well tolerated when administered as a single oral dose of 3 mg alone or coadministered with fluvoxamine, itraconazole, or rifampin"><entity charOffset="1-10" id="DDI-PubMed.31172535.s15.e0" text="Avadomide" /><entity charOffset="107-118" id="DDI-PubMed.31172535.s15.e1" text="fluvoxamine" /><entity charOffset="120-132" id="DDI-PubMed.31172535.s15.e2" text="itraconazole" /><entity charOffset="137-145" id="DDI-PubMed.31172535.s15.e3" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e0" e2="DDI-PubMed.31172535.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e0" e2="DDI-PubMed.31172535.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e0" e2="DDI-PubMed.31172535.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e0" e2="DDI-PubMed.31172535.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e1" e2="DDI-PubMed.31172535.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e1" e2="DDI-PubMed.31172535.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e1" e2="DDI-PubMed.31172535.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e2" e2="DDI-PubMed.31172535.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31172535.s15.e2" e2="DDI-PubMed.31172535.s15.e3" /></sentence><sentence text=" These results should serve as the basis for avadomide dose recommendations when it is coadministered with strong CYP3A and CYP1A2 inhibitors and with rifampin"><entity charOffset="45-54" id="DDI-PubMed.31172535.s16.e0" text="avadomide" /><entity charOffset="151-159" id="DDI-PubMed.31172535.s16.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31172535.s16.e0" e2="DDI-PubMed.31172535.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31172535.s16.e0" e2="DDI-PubMed.31172535.s16.e1" /></sentence><sentence text="" /></document>